{
    "info": {
        "nct_id": "NCT04280848",
        "official_title": "Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma",
        "inclusion_criteria": "* Male or female patients, age ≥ 18 and ≤ 75 years old\n* Written informed consent\n* Histologically confirmed glioblastoma\n* Patient with known MGMT status:\n\nCohort A (recruitment closed) : unmethylated MGMT status ; Cohort B (recruiting) : unmethylated or methylated MGMT status\n\n* Patients previously pre-treated with standard radiochemotherapy (without the additional cures of temozolomide.)\n* Karnofsky Performance status ≥ 70%\n* Life-expectancy > 3 months\n* Adequate hematological, hepatic, and renal function.\n* Females must be using highly effective contraceptive measures , and have a negative pregnancy test prior to the start of dosing if of childbearing potential, or must have evidence of non-childbearing potential.\n\nFemales of childbearing potential should use reliable methods of contraception from the time of the screening until 5 weeks after discontinuing study treatment.\n\nMale patients with a female partner of childbearing potential should be willing to use barrier contraception during the study and for 5 months following discontinuation of study drug. Patients should refrain from donating sperm from the start of dosing until 5 months after discontinuing study treatment.\n\n- Affiliation to French social security or receiving such a regime.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
        "exclusion_criteria": "* Presence of known extracranial metastatic or leptomeningeal disease Glioblastoma with mutated IDH1 (assessed by Immunohistochemistry)\n* Current or recent treatment with another investigational drug\n* Carmustine implant during surgery\n* History of autoimmune diseases (lupus, rheumatoid arthritis, inflammatory bowel disease...)\n* Prohibited medications:\n\n  1. Chronic treatment with immunosuppressive drugs\n  2. Ongoing requirement for supraphysiologic steroid defined as >10 mg prednisone daily (or equivalent)\n  3. Treatment with therapeutic oral or IV antibiotics within 4 weeks prior to enrollment. Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or pulmonary disease) are eligible for the study\n* Known positive serology for Human Immunodeficiency Virus (HIV) or Hepatitis C virus (HCV); presence in the serum of the antigens HBs\n* Non-hematologic toxicities Grade >1 severity (or, at the investigator's discretion, Grade >2 if not considered a safety risk for the patient).\n* Patient with intra-alveolar hemorrhage, pulmonary fibrosis, or uncontrolled asthma, or chronic obstructive disease (COPD), defined as at least 1 hospitalization within 4 months prior to enrollment or as at least 3 exacerbations during the last year prior to enrollment Hospitalization for cardiovascular or pulmonary disease within 4 weeks prior to enrollment.\n* Patients with LEVF<40%\n* Participation in a clinical study with an investigational product within 4 weeks prior to the start of the study treatment or patient in the exclusion period of a previous clinical trial.\n* Pregnancy or lactating patients.\n* Patients with any severe/uncontrolled inter current illness, significant co morbid or psychiatric conditions that in the opinion of the investigator would impair study participation or cooperation.\n* Patients under guardianship, curatorship or under the protection of justice.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Male or female patients, age ≥ 18 and ≤ 75 years old",
            "criterions": [
                {
                    "exact_snippets": "Male or female patients",
                    "criterion": "gender",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "age ≥ 18 and ≤ 75 years old",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 75,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Written informed consent",
            "criterions": [
                {
                    "exact_snippets": "Written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "form",
                            "expected_value": "written"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed glioblastoma",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed glioblastoma",
                    "criterion": "glioblastoma",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient with known MGMT status:",
            "criterions": [
                {
                    "exact_snippets": "known MGMT status",
                    "criterion": "MGMT status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Cohort A (recruitment closed) : unmethylated MGMT status ; Cohort B (recruiting) : unmethylated or methylated MGMT status",
            "criterions": [
                {
                    "exact_snippets": "Cohort A ... unmethylated MGMT status",
                    "criterion": "MGMT status",
                    "requirements": [
                        {
                            "requirement_type": "methylation",
                            "expected_value": "unmethylated"
                        }
                    ]
                },
                {
                    "exact_snippets": "Cohort B ... unmethylated or methylated MGMT status",
                    "criterion": "MGMT status",
                    "requirements": [
                        {
                            "requirement_type": "methylation",
                            "expected_value": [
                                "unmethylated",
                                "methylated"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients previously pre-treated with standard radiochemotherapy (without the additional cures of temozolomide.)",
            "criterions": [
                {
                    "exact_snippets": "Patients previously pre-treated with standard radiochemotherapy",
                    "criterion": "pre-treatment with standard radiochemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "without the additional cures of temozolomide",
                    "criterion": "additional cures of temozolomide",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Karnofsky Performance status ≥ 70%",
            "criterions": [
                {
                    "exact_snippets": "Karnofsky Performance status ≥ 70%",
                    "criterion": "Karnofsky Performance status",
                    "requirements": [
                        {
                            "requirement_type": "performance status",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life-expectancy > 3 months",
            "criterions": [
                {
                    "exact_snippets": "Life-expectancy > 3 months",
                    "criterion": "life-expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hematological, hepatic, and renal function.",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematological ... function.",
                    "criterion": "hematological function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... hepatic ... function.",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... renal function.",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Females must be using highly effective contraceptive measures , and have a negative pregnancy test prior to the start of dosing if of childbearing potential, or must have evidence of non-childbearing potential.",
            "criterions": [
                {
                    "exact_snippets": "Females must be using highly effective contraceptive measures",
                    "criterion": "contraceptive measures",
                    "requirements": [
                        {
                            "requirement_type": "effectiveness",
                            "expected_value": "highly effective"
                        }
                    ]
                },
                {
                    "exact_snippets": "have a negative pregnancy test prior to the start of dosing",
                    "criterion": "pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "if of childbearing potential",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "of childbearing potential"
                        }
                    ]
                },
                {
                    "exact_snippets": "must have evidence of non-childbearing potential",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "non-childbearing potential"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Females of childbearing potential should use reliable methods of contraception from the time of the screening until 5 weeks after discontinuing study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Females of childbearing potential",
                    "criterion": "gender and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": "females of childbearing potential"
                        }
                    ]
                },
                {
                    "exact_snippets": "should use reliable methods of contraception",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "necessity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "from the time of the screening until 5 weeks after discontinuing study treatment",
                    "criterion": "contraception duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": "from the time of the screening until 5 weeks after discontinuing study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Male patients with a female partner of childbearing potential should be willing to use barrier contraception during the study and for 5 months following discontinuation of study drug. Patients should refrain from donating sperm from the start of dosing until 5 months after discontinuing study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Male patients",
                    "criterion": "gender",
                    "requirements": [
                        {
                            "requirement_type": "expected gender",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "female partner of childbearing potential",
                    "criterion": "partner's childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "should be willing to use barrier contraception during the study and for 5 months following discontinuation of study drug",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the study and for 5 months following discontinuation of study drug"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients should refrain from donating sperm from the start of dosing until 5 months after discontinuing study treatment",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "refrain from donating",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "from the start of dosing until 5 months after discontinuing study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "- Affiliation to French social security or receiving such a regime.",
            "criterions": [
                {
                    "exact_snippets": "Affiliation to French social security",
                    "criterion": "affiliation to French social security",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "receiving such a regime",
                    "criterion": "receiving French social security regime",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "volunteer health status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "healthy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 75 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 75 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 75,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Presence of known extracranial metastatic or leptomeningeal disease Glioblastoma with mutated IDH1 (assessed by Immunohistochemistry)",
            "criterions": [
                {
                    "exact_snippets": "Presence of known extracranial metastatic ... disease",
                    "criterion": "extracranial metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Presence of known ... leptomeningeal disease",
                    "criterion": "leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Glioblastoma with mutated IDH1",
                    "criterion": "IDH1 mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Glioblastoma with mutated IDH1",
                    "criterion": "glioblastoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current or recent treatment with another investigational drug",
            "criterions": [
                {
                    "exact_snippets": "Current or recent treatment with another investigational drug",
                    "criterion": "treatment with another investigational drug",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": "current or recent"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Carmustine implant during surgery",
            "criterions": [
                {
                    "exact_snippets": "Carmustine implant during surgery",
                    "criterion": "Carmustine implant",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of autoimmune diseases (lupus, rheumatoid arthritis, inflammatory bowel disease...)",
            "criterions": [
                {
                    "exact_snippets": "History of autoimmune diseases (lupus, rheumatoid arthritis, inflammatory bowel disease...)",
                    "criterion": "autoimmune diseases",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prohibited medications:",
            "criterions": [
                {
                    "exact_snippets": "Prohibited medications",
                    "criterion": "medications",
                    "requirements": [
                        {
                            "requirement_type": "prohibition",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Chronic treatment with immunosuppressive drugs",
            "criterions": [
                {
                    "exact_snippets": "Chronic treatment with immunosuppressive drugs",
                    "criterion": "immunosuppressive drug treatment",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": "chronic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Ongoing requirement for supraphysiologic steroid defined as >10 mg prednisone daily (or equivalent)",
            "criterions": [
                {
                    "exact_snippets": "Ongoing requirement for supraphysiologic steroid defined as >10 mg prednisone daily (or equivalent)",
                    "criterion": "supraphysiologic steroid",
                    "requirements": [
                        {
                            "requirement_type": "ongoing requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg prednisone daily"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Treatment with therapeutic oral or IV antibiotics within 4 weeks prior to enrollment. Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or pulmonary disease) are eligible for the study",
            "criterions": [
                {
                    "exact_snippets": "Treatment with therapeutic oral or IV antibiotics within 4 weeks prior to enrollment.",
                    "criterion": "treatment with therapeutic antibiotics",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "route of administration",
                            "expected_value": [
                                "oral",
                                "IV"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients receiving prophylactic antibiotics ... are eligible for the study",
                    "criterion": "prophylactic antibiotics",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known positive serology for Human Immunodeficiency Virus (HIV) or Hepatitis C virus (HCV); presence in the serum of the antigens HBs",
            "criterions": [
                {
                    "exact_snippets": "Known positive serology for Human Immunodeficiency Virus (HIV)",
                    "criterion": "HIV serology",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "Known positive serology for ... Hepatitis C virus (HCV)",
                    "criterion": "HCV serology",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "presence in the serum of the antigens HBs",
                    "criterion": "HBs antigen",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Non-hematologic toxicities Grade >1 severity (or, at the investigator's discretion, Grade >2 if not considered a safety risk for the patient).",
            "criterions": [
                {
                    "exact_snippets": "Non-hematologic toxicities Grade >1 severity",
                    "criterion": "non-hematologic toxicities",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at the investigator's discretion, Grade >2 if not considered a safety risk for the patient",
                    "criterion": "non-hematologic toxicities",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "Grade"
                            }
                        },
                        {
                            "requirement_type": "safety risk",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient with intra-alveolar hemorrhage, pulmonary fibrosis, or uncontrolled asthma, or chronic obstructive disease (COPD), defined as at least 1 hospitalization within 4 months prior to enrollment or as at least 3 exacerbations during the last year prior to enrollment Hospitalization for cardiovascular or pulmonary disease within 4 weeks prior to enrollment.",
            "criterions": [
                {
                    "exact_snippets": "intra-alveolar hemorrhage",
                    "criterion": "intra-alveolar hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pulmonary fibrosis",
                    "criterion": "pulmonary fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled asthma",
                    "criterion": "uncontrolled asthma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic obstructive disease (COPD)",
                    "criterion": "chronic obstructive disease (COPD)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 1 hospitalization within 4 months prior to enrollment",
                    "criterion": "hospitalization for COPD",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "hospitalizations"
                            }
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": "4 months prior to enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 3 exacerbations during the last year prior to enrollment",
                    "criterion": "exacerbations for COPD",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "exacerbations"
                            }
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": "last year prior to enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Hospitalization for cardiovascular or pulmonary disease within 4 weeks prior to enrollment",
                    "criterion": "hospitalization for cardiovascular or pulmonary disease",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": "4 weeks prior to enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with LEVF<40%",
            "criterions": [
                {
                    "exact_snippets": "LEVF<40%",
                    "criterion": "LEVF",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 40,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participation in a clinical study with an investigational product within 4 weeks prior to the start of the study treatment or patient in the exclusion period of a previous clinical trial.",
            "criterions": [
                {
                    "exact_snippets": "Participation in a clinical study with an investigational product within 4 weeks prior to the start of the study treatment",
                    "criterion": "participation in a clinical study with an investigational product",
                    "requirements": [
                        {
                            "requirement_type": "time since participation",
                            "expected_value": {
                                "operator": "<",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patient in the exclusion period of a previous clinical trial",
                    "criterion": "exclusion period of a previous clinical trial",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnancy or lactating patients.",
            "criterions": [
                {
                    "exact_snippets": "Pregnancy",
                    "criterion": "pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating patients",
                    "criterion": "lactation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with any severe/uncontrolled inter current illness, significant co morbid or psychiatric conditions that in the opinion of the investigator would impair study participation or cooperation.",
            "criterions": [
                {
                    "exact_snippets": "any severe/uncontrolled inter current illness",
                    "criterion": "inter current illness",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe/uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "significant co morbid ... conditions",
                    "criterion": "co morbid conditions",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "significant ... psychiatric conditions",
                    "criterion": "psychiatric conditions",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients under guardianship, curatorship or under the protection of justice.",
            "criterions": [
                {
                    "exact_snippets": "Patients under guardianship",
                    "criterion": "guardianship",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "curatorship",
                    "criterion": "curatorship",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "under the protection of justice",
                    "criterion": "protection of justice",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}